SUDEP, hence no 'SUDEP risk profile' is available for SUDEP prevention.
In previous studies a number of risk factors has been identified such as male gender, 3, [10] [11] [12] [13] [14] [15] an age of 20-45 years, 9, 16, 17 generalized tonic-clonic seizures, [9] [10] [11] 15, [17] [18] [19] high seizure frequency, 6, 17, [20] [21] [22] long duration of epilepsy, 17, 18, 22 psychiatric comorbidity 17, 23 and/or mental retardation. 4, 17, 20 In many cases, there is evidence of a terminal epileptic seizure. 4, 11, 16, 17, 19, [24] [25] [26] SUDEP occurs relatively more frequently during sleep or while lying in bed. 10, 16, 19, 20, 27 It is not clear whether SUDEP occurs more in symptomatic or idiopathic epilepsy. 9, 11, 15, 18 Some authors have shown the influence of specific antiepileptic drugs (AEDs), 15, 28, 29 in particular those affecting cardiac rhythm such as sodium channel blockers. However, in most studies specific AEDs did not play a role in SUDEP. 4, 14, 16, 19, [30] [31] [32] Also treatment with multiple AEDs is suggested to be a risk factor for SUDEP, 4, 18, 22, 33 whereas other studies could not confirm this factor 13, 15, 16, 19 or interfering factors have been found, such as the severity of the epilepsy. 20, 34, 35 Pathophysiological mechanisms underlying SUDEP have been suggested to be central apnea 24, 30, [36] [37] [38] [39] or cardiac arrhythmia. 37, [40] [41] [42] [43] [44] [45] [46] [47] The purpose of this study is to evaluate risk factors for SUDEP in a high-risk population, i.e. patients treated (both clinically and on an outpatient basis) in a Dutch tertiary referral center for epilepsy ('Kempenhaeghe').
Methods

Study population
Epilepsy center Kempenhaeghe in Heeze is a tertiary referral center in the south eastern part of the Netherlands that provides services for patients from all parts of our country. The population base for this study were deaths that occurred within the epilepsy population treated in the period between January 1999 and April 2004. The population is characterized by a high percentage of patients with severe or intractable epilepsy. In this study, we compared the SUDEP group with control subjects with a history of epilepsy who died from other causes than SUDEP.
SUDEP definition
We used Leestma's criteria for SUDEP: the victim suffered from epilepsy, the victim died unexpectedly in a reasonable state of health, death occurred 'suddenly' (in minutes), when known, death occurred during normal activities and benign circumstances, an obvious medical cause of death was not found at post-mortem examination and death was not the direct result of the seizure or status epilepticus. 1, 14 'Definite SUDEP' cases meet all criteria, 'probable SUDEP' cases meet all criteria but lack post-mortem data, 'possible SUDEP' are cases where SUDEP cannot be ruled out but available information is not conclusive and post-mortem data are lacking, and non-SUDEP are those cases in which another cause of death is clear or SUDEP is highly improbable. Working definitions for SUDEP include both definite and probable SUDEP, because postmortem examinations are not routinely performed in the Netherlands.
Assessment of clinical variables
An electronical patient record system available in Kempenhaeghe facilitates easy and reliable access to data for large patient groups. Using this system the patient's medical history could be extracted. For each death the following data were included in a database and evaluated: epilepsy syndrome, type of seizures, status epilepticus, age at seizure onset, seizure frequency in the last year before death, race, age at death, last AED therapy, comedication (antihypertensive, pulmonary, cardiac and antipsychotic medication, betablockers, anticoagulants), comorbidity -such as cardiovascular disease, pulmonary disease, stroke, diabetes, mental retardation and psychiatric illness including dementiaalcohol and other substance abuse, EEG abnormalities, epilepsy localization, circumstances of death and results of autopsy (if present). Classification of epilepsy syndrome and seizure type occurred according to the International League Against Epilepsy system. Family doctors were asked about the death circumstances when documentation in Kempenhaeghe was not conclusive. Data were evaluated by two neurologists specialized in epilepsy, to categorize the patients in non-, possible, probable or definite SUDEP groups. If there was any reason to suspect that the patient had died of another cause than SUDEP, for example because of existing comorbidity or old age, this patient was included in the non-SUDEP group.
Statistical analysis
All data were entered in a database and evaluated using the SPSS statistical program. Descriptives (means, S.D. and frequencies) were evaluated. For all variables correlations (crosstabs, with Chi-square non-parametric testing) between SUDEP and the clinical variables were calculated. p-Values < .05 (one-sided) were regarded as statistically significant. Those clinical variables that yielded a statistically significant relationship with SUDEP the differential contribution was evaluated with linear regression with SUDEP as the dependent variable.
Ethics approval was obtained from the ethics committee of Epilepsy Center Kempenhaeghe, Heeze.
Results
From January 1999 to April 2004, a mean number of 4400 people with epilepsy were treated per year by the epilepsy center and 274 deaths were reported at Kempenhaeghe. Of those, 95 were excluded because they were not suffering from epilepsy or they had not been under treatment of Kempenhaeghe when they died. From the remaining 179 patients, cause of death was not identified in 25 patients, 104 patients died from other causes than SUDEP, 21 patients were classified as possible SUDEP, 24 as probable SUDEP and five patients died of definite SUDEP (Table 1) . Our SUDEP group consists of 'definite plus probable SUDEP' cases, that is 29 patients. Presuming that the unknown cases were non-SUDEP, 16 .2% of deaths in this period were caused by SUDEP. A higher percentage would be the result of omitting the unknown cases from the analysis (18.8%) or presuming all the unknown cases are due to SUDEP (30.2%). The 104 patients who died of other causes than SUDEP form the control group.
Demography
The age at death in the SUDEP group ranged from 4 to 69 years and in the control group 1-90 years. The SUDEP group was significantly younger than the control group (mean 29.0 AE 16.0 S.D. versus 52.5 AE 23.1 years with p = 0.016) at time of death.
In the SUDEP group, 45% were male, 55% female and in the control group 52% male and 48% female. Although the female proportion was greater in the SUDEP group, Chi-square analysis indicated that this was not significant ( p = 0.321). Table 2) .
Clinical features
Number of seizures was not significantly different between SUDEP cases and controls. In the control group, relatively more patients were seizure free for at least 1 year before death, but this was not significant ( p = 0.220).
SUDEP subjects had more generalized tonic-clonic seizures -partial seizures secondarily generalized and/or primary generalized tonic-clonic seizures -than controls, but this was not statistically significant ( p = 0.292). We also performed statistical analysis for all separate seizure types, but none of the comparisons reached a statistically significant correlation with SUDEP. There was no correlation between SUDEP and type of epilepsy (divided into idiopathic, symptomatic or cryptogenic epilepsy); also no correlation was seen between SUDEP and EEG abnormalities or the localization of the seizures or other EEG-data.
The SUDEP group showed less comorbidity than controls. SUDEP subjects had significantly less cardiovascular and pulmonary disease than controls (respectively, p = 0.008 and p = 0.046). Stroke and diabetes mellitus were observed less frequently in the SUDEP group, but this was not statistically significant. Mental retardation and psychiatric illness occurred slightly more frequently in SUDEP subjects, but this was also not statistically significant.
Medication details
None of the AEDs that were used by the subjects in this study had a statistically significant correlation with SUDEP. A combination of sodium channel blockers (carbamazepine, oxcarbazepine and phenytoin) did not show a correlation with SUDEP either. The were no statistically significant differences between SUDEP and non-SUDEP subjects. Table 3 shows the main characteristics of the 29 SUDEP patients.
For those three factors that reached a statistically significant correlation with SUDEP, that is age at death, age at onset and duration of epilepsy, linear regression analysis was performed. The previously mentioned factors were used as predictors and SUDEP as the dependent variable. Regression analysis was carried out to inspect the differential contribution of each of these factors in relation to SUDEP. Regression analysis showed that only one factor, age at death, correlated statistically significantly with SUDEP after removal of the intercorrelation between those factors ( p < 0.001; Beta = À0.370; R square = 0.14), explaining 14% of the total variance of factors predicting SUDEP.
Discussion
In this study we analyzed the correlation between SUDEP and a wide range of factors reported in previous studies as risk factors. Our study evaluated patients, treated in an epilepsy center with a high percentage of patients suffering from chronic refractory epilepsy. A high percentage of SUDEP cases was found (16.2% of the total deaths in the evaluated period of 5 years and 3 months). We found a SUDEP rate of 1.24 per 1000 patient years in the epilepsy population of the epilepsy center. Other studies report SUDEP rates up to 9.30 per 1000 patient years; highest in cohorts with surgical candidates. 48 However, in studies performed at epilepsy centers and epilepsy referrals, SUDEP rates reported range from 2 to 5.9 per 1000 patient years. 1, 12, 15, 49, 50 Our data therefore show a lower yearly incidence of SUDEP than reported in other studies. We conclude that SUDEP cannot be considered as a frequently occurring phenomenon.
There were only three differences between the SUDEP and the non-SUDEP subjects that reached statistical significance. In the SUDEP group, subjects died at a significantly younger age than in the non-SUDEP group. Furthermore, age at onset of epilepsy was younger than in controls. This finding concurs with some studies, 19, 22 but conflicts with other data. 16 The duration of epilepsy was significantly shorter than in controls. This finding is in contrast with most previous studies which reported a longer or no difference in duration of epilepsy in SUDEP groups compared to controls. 11, 15, 16, 50 We believe that our finding can be partly attributed to the difference in age at death between SUDEP and control groups (mean 29.00 years versus mean 52.52 years).
For those three factors that reached a statistically significant correlation with SUDEP, that is age at death, age at onset and duration of epilepsy, linear regression analysis showed that only age at death correlated statistically significantly with SUDEP. Our finding that the SUDEP group was significantly younger than the control group concurs with most previous studies that indicated young adults to be particularly at risk for SUDEP. 3, 9, 11, 14, 16, 17, 50 Young (adult) age at death can however not be seen as a real risk factor for SUDEP. Part of this difference in age at death can be explained by the definition of SUDEP. In elderly people deaths are more likely to be attributed to the presence of comorbidity, for example cardiovascular or pulmonary disease, or to old age itself which causes that SUDEP in the higher age ranges will go undetected. Most studies suggest that SUDEP occurs more commonly in male subjects, 3, [10] [11] [12] [13] 15 but some like our study find no association between SUDEP and gender. 19 Most of the SUDEP subjects had generalized tonic-clonic seizures (76%), confirming previous studies, 4, [9] [10] [11] 15, 17, 19, 30, 47 although this differed not much from the control group (68%).
SUDEP in the Netherlands
We could not confirm previous studies that reported a correlation between SUDEP and particular epilepsy types, 9, 15, 18 in agreement with two other studies. 11, 16 Where most studies reported higher SUDEP occurrence in subjects with frequent seizures, 2, 14, 15, 17, 22, 50, 51 some like our study find no correlation between SUDEP and a high seizure frequency. 15, 16, 19 We could not prove a significant difference in epilepsy localization between SUDEP and non-SUDEP subjects.
No significant differences were found in comorbidity. Cardiovascular and pulmonary disease was reported less in the SUDEP subjects than in controls, but we believe this can be attributed to the age differences and to SUDEP definitions. Subjects with major comorbidity were more likely to be diagnosed as possible or non-SUDEP than healthy subjects. Mental retardation and psychiatric illness were reported slightly more in the SUDEP group, but this was not significant. These findings are in contrast with previous reports of association of SUDEP with mental retardation 4, 17, 20 and psychiatric illness, 17, 23 but agree with another study that did not confirm an association. 16 We found no significant differences in medication between SUDEP and control groups. No particular AED was associated with SUDEP, confirming previous studies, 16, 17, 19, 30 but in contrast with other studies. 28, 35, 52 Polytherapy with AEDs was not confirmed to be a risk factor for SUDEP, in agreement with previous reports, 13, 16, 19, 28 but differing from other studies. 4, 22, 30, 33 This finding may be related to the high percentage of subjects with severe epilepsy, and as a consequence a high percentage of subjects on polytherapy, in both the SUDEP as the control groups. In comedication, SUDEP subjects used significantly less antihypertensive medication, probably as a result of both younger age and less cardiovascular disease in this group. Other comedication did not differ appreciably between our groups. In particular, this contrasts with previous findings that psychotropic medication is likely to be associated with SUDEP. 33 Previous studies reported signs of seizures, for example fresh bites, cyanosis or blood on the pillow, preceding death in most of SUDEP subjects. 11, 14, 16, 19 In our study, we also see a trend towards deaths preceded by seizures, but data were not sufficient to compare with the control group. However, SUDEP did also occur in subjects who had been seizure free in the last 12 months before their death. Most of the SUDEP subjects were found in bed and where position at death was reported, prone position was frequently the case. Unfortunately, we cannot compare these findings with results from the control group, because these data are lacking about the control subjects.
In conclusion even in this high-risk population of patients with a refractory epilepsy, treated in a tertiary referral center, SUDEP occurs a fourfold times more than in the overall population of epilepsy patients, but is not as frequent as reported in other studies with highly selected patients populations. In absolute numbers it is not a frequently occurring phenomenon with a yearly incidence of 1.24/1000. Our study showed that SUDEP patients died at a younger age than a control group of non-SUDEP deaths with epilepsy and had an earlier onset of epilepsy but no real risk factors could be identified. The frequently mentioned factors in previous studies, i.e. male gender, generalized tonic-clonic seizures, high seizure frequency, particular AEDs, polytherapy of AEDs, mental retardation, psychiatric illness and psychotropic comedication, were not found to be correlated with SUDEP in our study.
